Cintia Piccina Biography and Net Worth

Insider of Autolus Therapeutics

Cintia Piccina was appointed U.S. Chief Commercial Officer and Country General Manager in 2025 to lead ongoing momentum in AUCTAZYL® U.S. launch and drive future growth. Cintia brings to Autolus extensive cellular therapy experience having led teams that successfully launched and commercialized multiple products with Novartis, Bluebird/2seventy bio, Allovir and Adaptimmune, where she was most recently the Chief Commercial Officer.

What is Cintia Piccina's net worth?: The estimated net worth of Cintia Piccina is at least $25.84 thousand as of September 2nd, 2026. Piccina owns 13,287 shares of Autolus Therapeutics stock worth more than $25,843 as of September 14th. This net worth estimate does not reflect any other investments that Piccina may own. Learn More about Cintia Piccina's net worth.
How do I contact Cintia Piccina?: The corporate mailing address for Piccina and other Autolus Therapeutics executives is The Mediaworks, 191 Wood Lane, London, X0, W12 7fp. Autolus Therapeutics can also be reached via phone at 442038296230 and via email at [email protected]. Learn More on Cintia Piccina's contact information.
Has Cintia Piccina been buying or selling shares of Autolus Therapeutics?: During the last ninety days, Cintia Piccina has sold $15,708.42 of Autolus Therapeutics stock. Most recently, Cintia Piccina sold 6,713 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $2.34, for a transaction totalling $15,708.42. Following the completion of the sale, the insider now directly owns 13,287 shares of the company's stock, valued at $31,091.58. Learn More on Cintia Piccina's trading history.
Are insiders buying or selling shares of Autolus Therapeutics?: During the last year, insiders at the sold shares 1 times. They sold a total of 6,713 shares worth more than $15,708.42. The most recent insider tranaction occured on September, 2nd when insider Cintia Piccina sold 6,713 shares worth more than $15,708.42. Insiders at Autolus Therapeutics own 25.7% of the company. Learn More about insider trades at Autolus Therapeutics.
Information on this page was last updated on 9/2/2026.

Cintia Piccina Insider Trading History at Autolus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/2/2026	Sell	6,713	$2.34	$15,708.42	13,287

Cintia Piccina Buying and Selling Activity at Autolus Therapeutics

Autolus Therapeutics Company Overview

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Today's Range

Now: $1.95

$1.85

$1.95

50 Day Range

MA: $1.93

$1.40

$2.54

2 Week Range

Now: $1.95

$1.18

$2.58

Volume

1,320,651 shs

Average Volume

1,808,927 shs

Market Capitalization

$517.68 million

P/E Ratio

N/A

Dividend Yield